Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2017 11:12 ET | Source: Genmab A/S

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma

Company Announcement sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma...
November 21, 2017 09:34 ET | Source: Genmab A/S

Data from Phase III ALCYONE Study of Daratumumab Accepted for Oral Presentation at Annual Meeting of the American Society of Hematology

Media Release Late-breaking abstract accepted for oral presentation Data from Phase III ALCYONE study of daratumumab in combination with bortezomib, melphalan and prednisone in front line...
November 21, 2017 06:58 ET | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma

Company Announcement Application to broaden label for daratumumab in front line multiple myeloma submitted to EMA Submission based on data from Phase III ALCYONE study Genmab to...
November 16, 2017 21:30 ET | Source: Genmab A/S

Genmab Achieves USD 50 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

Company Announcement Genmab to receive milestone payment of USD 50 million in DARZALEX collaboration Milestone triggered by sales of DARZALEX reaching USD 1 billion in a calendar...
November 15, 2017 15:40 ET | Source: Genmab A/S

Articles of Association for Genmab A/S

Genmab A/S has published its Articles of Association dated November 14, 2017. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel...
November 15, 2017 15:40 ET | Source: Genmab A/S

Selskabsvedtægter for Genmab A/S

Selskabsvedtægter for Genmab A/S dateret den 14. november 2017 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
November 14, 2017 14:49 ET | Source: Genmab A/S

Genmab Achieves USD 25 Million Milestone for First Commercial Sale of DARZALEX® (daratumumab) in Japan and Updates Financial Guidance

Company Announcement First commercial sale of DARZALEX in Japan triggers USD 25 million in milestone payments from Janssen Financial guidance updated Copenhagen, Denmark; November 14,...
November 14, 2017 12:19 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; November 14, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 22,532 shares as a consequence of the exercise of employee...
November 09, 2017 14:33 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; November 9, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29 of the...
November 08, 2017 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2017

November 8, 2017; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2017 Highlights USD 871 million in net sales of DARZALEX® (daratumumab); resulting in...